Jeff Meacham

I want to get some perspectives from you on penetration into primary prevention and where it could go

on Pumitamig, I wanted to check on the cadence of data in, say, the next 6 to 12 months?

just to talk through the Qvantig dynamics versus Opdivo and where you're seeing the biggest demand?

give us a bit more context for not moving to Phase III, maybe what was observed in the data